

Electronic Acknowledgement Receipt

EFS ID:	6688439
Application Number:	10607623
International Application Number:	
Confirmation Number:	7907
Title of Invention:	Method of treating acute myocardial infarction
First Named Inventor/Applicant Name:	Haim D. Danenberg
Customer Number:	75004
Filer:	SONJA KEENAN
Filer Authorized By:	
Attorney Docket Number:	92114.005US1
Receipt Date:	22-DEC-2009
Filing Date:	27-JUN-2003
Time Stamp:	14:05:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	433
Deposit Account	504387
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part/.zip	Pages (if appl.)
1	Transmittal Letter	92114_005US1_Transmittal_Letter_December_2009.pdf	514028 e1ac547cc5ed8fc15a7b53865ec87caa78d8f1	no	4

Warnings:

Information:

2	Information Disclosure Statement (IDS) Filed (SB/08)	92114_005US1_1449A_December_2009.pdf	135545 84136474a1b1d2ebca3c3da9954439b6d5a6f4	no	1
---	--	--------------------------------------	--	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

3	Foreign Reference	WO96020698.pdf	5238958 addff0f6c918bea1d4ce1a3b1400be516166ff	no	171
---	-------------------	----------------	---	----	-----

Warnings:

Information:

4	Foreign Reference	WO9716170.pdf	4512633 6f90ccfe16e9ff6a19b29759945361bdcc1722eb	no	91
---	-------------------	---------------	---	----	----

Warnings:

Information:

5	Information Disclosure Statement (IDS) Filed (SB/08)	92114_005US1_1449B_December_2009.pdf	373660 c5172c8ebef21172fd299bc64e43fed1ed15	no	2
---	--	--------------------------------------	--	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

6	NPL Documents	Kramsch_Reference.pdf	1273394 3600995d49e13a135d46e213238b5f7a09813	no	11
---	---------------	-----------------------	--	----	----

Warnings:

Information:

7	NPL Documents	Monkkonen_Reference_J_Drug_Target_1994.pdf	1796619 222803d36f03e88d0817c22fb91a1095bc3d7b	no	10
---	---------------	--	---	----	----

Warnings:

Information:

8	NPL Documents	Donbrow_Reference_1992.pdf	20535872 760300e197be9ff0f088adcf5ed83ca5c090 1b92a	no	358
---	---------------	----------------------------	---	----	-----

Warnings:**Information:**

9	NPL Documents	Paspaliaris_Reference.pdf	490774 8fa36149713d70f9b59a2f216c09fb75f51 c5de	no	7
---	---------------	---------------------------	---	----	---

Warnings:**Information:**

10	NPL Documents	Van_Rooijen_Liposomes_Drug_Carrier_Chapter_9.pdf	854820 17a7b6fb4b5a6b301294471989c03fbef 5c728	no	15
----	---------------	--	--	----	----

Warnings:**Information:**

11	NPL Documents	Thepen_Reference.pdf	1146871 361e2ef7cbedeb5a2de74adaf2a7e7116f 115c	no	11
----	---------------	----------------------	---	----	----

Warnings:**Information:**

12	NPL Documents	Monkkonen_Reference_Pharm_a_Toxicol_1991.pdf	290740 ed117ce128874ae7748e98554294c5be957 d8c18	no	3
----	---------------	--	--	----	---

Warnings:**Information:**

13	NPL Documents	Van_Rooijen_Reference_Res_Immunol_1992.pdf	567412 459142a8729e73f53d498cc2f5bdcb7f6 8019	no	3
----	---------------	--	---	----	---

Warnings:**Information:**

14	NPL Documents	Biewenga_Reference_Cell_Tissue_Res_1995.pdf	1731892 6810cd736521916ddc823d6500673ae5 c3e61	no	8
----	---------------	---	--	----	---

Warnings:**Information:**

15	NPL Documents	Gaytan_Reference.pdf	790597 62304a6b702e14481e177ad4eb27094c 46259	no	9
----	---------------	----------------------	---	----	---

Warnings:**Information:**

16	NPL Documents	Van_Rooijen_Reference_Trends_Biotech_1997.pdf	1638865 d541bf1b2e231693b1388ea9e6691c785a 79def	no	8
----	---------------	---	--	----	---

Warnings:**Information:**

17	NPL Documents	Van_Rooijen_J_Leuk_Biol_1989.pdf	1050112 40d0012aeff0e64f1204493e01a3a18f1397e0fe5	no	10
----	---------------	----------------------------------	--	----	----

Warnings:**Information:**

18	NPL Documents	Van_Rooijen_Seminars_Immunology_1992.pdf	818657 7a907d61206dc1a31a26d1a84f70e70539 c7b4	no	10
----	---------------	--	--	----	----

Warnings:**Information:**

19	NPL Documents	Clodronate_Liposome_Printout.pdf	39165 a6dbab4ab2b5b6edc019552-1/95.900-efc e75ec7	no	1
----	---------------	----------------------------------	---	----	---

Warnings:**Information:**

20	NPL Documents	Van_Rooijen_Reference_Virchow_1988.pdf	1112681 3e33bc090c07412a4ebf955 (c5f6e6590cb 43ac	no	5
----	---------------	--	---	----	---

Warnings:**Information:**

21	NPL Documents	Van_Rooijen_J_Immuno_Methds_1994.pdf	2467516 7a2d02002a379b528c3ab5b13423176(9 a234b	no	11
----	---------------	--------------------------------------	---	----	----

Warnings:**Information:**

22	NPL Documents	Langer_Science_1990.pdf	2436869 7510fb8111152-99213a2a93546f16c 0bd74	no	8
----	---------------	-------------------------	---	----	---

Warnings:**Information:**

23	NPL Documents	Cohen_Pharma_Res_1999.pdf	1211240 b62a6eab9300f19b721bd6d9b99a2f6fb 3535	no	8
----	---------------	---------------------------	--	----	---

Warnings:**Information:**

24	NPL Documents	11190787_Interview_Summary_November_2009.pdf	165773 17ca4f9a1f96700a6061c5d65a899464c 207c	no	3
----	---------------	--	---	----	---

Warnings:**Information:**

25	NPL Documents	Buiting_Reference.pdf	933999 6674f824a5a1990e155705c18bea93a ae46c	no	10
----	---------------	-----------------------	--	----	----

Warnings:**Information:**

26	NPL Documents	Bergh_Reference.pdf	1461741 b7c6f144b53a3e6d361001379cb0f3ca10 865	no	11
Warnings:					
Information:					
27	NPL Documents	Van_Rooijen_J_Immunol_Meth ods_1996.pdf	543586 3e7eb2020fb1cb6d5d773ad41171d838e 7416	no	7
Warnings:					
Information:					
28	NPL Documents	Leenaars_Reference.pdf	815995 8e1902a6d42a1007c18-15d91b90375987 d187b	no	7
Warnings:					
Information:					
29	Fee Worksheet (PTO-875)	fee-info.pdf	29932 add1fe987d8c5d5bf7965bf70e3e1170c54 66	no	2
Warnings:					
Information:					
Total Files Size (in bytes):				54979946	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					